Conference Coverage
Latest News
Feb 12, 2026 | News
FDA approves label changes for first batch of menopausal hormone therapy products
MDT associated with prolonged PFS in oligometastatic prostate cancer
Feb 12, 2026
The Expert APProach: Behind the Scenes of Neuro-Urology Care, with Michael Ritmiller, PA-C, MPAS
Feb 12, 2026
Pearls & Perspectives: Expanding Options in Male Incontinence, with Laura Horodyski, MD
Feb 11, 2026
Oxybutynin superior to placebo in reducing ADT-associated hot flashes
Feb 11, 2026
Advertisement
Shorts
0:55
What are some benefits of multiport robotic partial nephrectomy?
an hour ago
by
Savannah Grandy, DO
0:54
The evolution of testicular cancer survivorship care
a day ago
by
Francisco Ramos, MD
1:07
How Break Wave allows for patient participation in kidney stone treatment
2 days ago
by
Mathew D. Sorensen, MD, MS
1:15
Christopher Filson, MD, shares data on study of CxBladder Triage
3 days ago
by
Christopher P. Filson, MD, MS
1:22
Veda Giri, MD, on patient education for genetic testing
6 days ago
by
Veda N. Giri, MD
1:01
Amy Luckenbaugh, MD, on advances in urologic oncology
7 days ago
by
Amy N. Luckenbaugh, MD
4:24
World Cancer Day: Honoring Patient Resilience and Recent Advances in Urologic Oncology
8 days ago
by
Hannah Clarke
1:11
Kate Kraft, MD, discusses how to build leadership presence as an introvert
8 days ago
by
Kate H. Kraft, MD, MHPE, FACS, FAAP
1:02
Amanda North, MD, discusses imposter syndrome and reframing your thinking
9 days ago
by
Amanda C. North, MD
1:12
Mathew D. Sorensen, MD, MS, FACS, on how Break Wave lithotripsy works without anesthesia
10 days ago
by
Mathew D. Sorensen, MD, MS
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
The findings offer insights into how treatment may be optimized using PSMA-PET/CT results.
The following FAQs highlight key guideline recommendations relevant to clinicians regarding the early detection of prostate cancer.
In this episode, host Amy Pearlman, MD, sits down with Emad Ibrahim, MD, HCLD, to discuss sexual and reproductive health in patients with spinal cord injury.
Adam B. Weiner, MD, is joined by Brian M. Shuch, MD, for a concise yet wide-ranging update on the evolving role of adjuvant therapy in renal cell carcinoma.
The conversation explores the growing role of at-home semen testing kits as screening tools, their advantages in accessibility and privacy, and their limitations compared with in-lab testing.
The study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of NEO-811 in ccRCC.
The sildenafil oral film is expected to be commercially available in the US in March 2026.
URO-1’s FDA-cleared SUREcore and coreCARE prostate biopsy devices have been adopted at multiple Novant Health hospitals as part of a systemwide value analysis.
The conversation explores evolving strategies that have further lowered infection risk, including no-touch principles, chlorhexidine skin preparation, antibiotic and customizable implant coatings, and growing interest in antiseptic-based solutions rather than antibiotics alone.
Advertisement
At 24 months, apalutamide demonstrated a statistically significant improvement in OS vs darolutamide without concurrent docetaxel.
Amy Pearlman, MD, sits down with Katherine A. Amin, MD, to discuss the evolving landscape of female pelvic medicine, overactive bladder management, and fellowship training.
The application is seeking approval of Signatera CDx as a companion diagnostic to select patients with MIBC for treatment with adjuvant atezolizumab.
A recap of the FDA submissions and regulatory decisions in urology from January 2025.
Advertisement
Advertisement
Trending on Urology Times
1
Oxybutynin superior to placebo in reducing ADT-associated hot flashes
2
The Expert APProach: Behind the Scenes of Neuro-Urology Care, with Michael Ritmiller, PA-C, MPAS
3
Pearls & Perspectives: Expanding Options in Male Incontinence, with Laura Horodyski, MD
4
PSMA-PET/CT–guided salvage radiotherapy yields favorable outcomes after prostatectomy
5